Low Serum 25(OH)D3 in Patients Newly Diagnosed With T2DM
(HealthDay News) — Serum 25-hydroxyvitamin D3 (25[OH]D3) is associated with glucose-stimulated insulin secretion and β-cell function in individuals with newly diagnosed type 2 diabetes, according to a study published online June 5 in the Journal of Diabetes Investigation.
Yan Yang, from the Sichuan Provincial People's Hospital in Chengdu, China, and colleagues recruited 97 newly diagnosed type 2 diabetes patients and 69 healthy controls to assess 25(OH)D3. The authors determined 25(OH)D3 using high pressure liquid chromatography. The correlations of 25(OH)D3 with insulin resistance and β-cell function were assessed.
The researchers found that patients with newly diagnosed type 2 diabetes had much lower serum 25(OH)D3 (P<0.01); the prevalence of hypovitaminosis 25(OH)D3 in patients with diabetes was 62.9%. Among patients with diabetes, those with hypovitaminosis 25(OH)D3 had higher hemoglobin A1c (HbA1c) and area under the curve for glucose (P<0.01) and lower homeostasis model of assessment (HOMA)-β, early-phase insulin secretion index, and area under the insulin curve. There was an independent positive correlation for serum 25(OH)D3 with early-phase insulin secretion index and area under the insulin curve (P<0.05), but not with HOMA-insulin resistance or HOMA-β. In both groups, triglycerides, HbA1c, and early-phase insulin secretion index were independent factors associated with serum 25(OH)D3.
"Serum 25(OH)D3 is not correlated with basal insulin resistance or β-cell function but is significantly positively correlated with glucose-stimulated insulin secretion and β-cell function," the authors write.